EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU Decision by the EC is expected in the third quarter of 2017 Not intended for UK-based media DARMSTADT, Germany and NEW YO... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, BAVENCIO, avelumab, metastatic Merkel cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news